Trial Protocol ID
XPORT-MF-044

Investigator
Mohit Narang, M.D.

A Phase 2 study to evaluate the efficacy and safety of selinexor monotherapy in subjects with JAK inhibitor (JAKi)-naïve myelofibrosis and moderate thrombocytopenia

Trial Protocol ID
SENTRY_XPORT-MF-034

Investigator
Mohit Narang, M.D.

A Phase 1/3 Study to Evaluate Efficacy and Safety of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Ruxolitinib in Treatment-naïve Patients With Myelofibrosis

Trial Protocol ID
AIS-D04_RUBY-4

Investigator
Mohit Narang, M.D.

A Phase 1b, Open-Label Study to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Povetacicept in Subjects with Autoimmune Cytopenias (RUBY-4)

Trial Protocol ID
USOR 23046_CVAY736Q12201_TPO_RA *STAR*

A phase 2 study to evaluate the efficacy and safety of ianalumab (VAY736) in patients with primary immune thrombocytopenia (ITP) previously treated with at least a corticosteroid and a thrombopoietin receptor agonist

Trial Protocol ID
USOR 18263_BGB-3111-215 *STAR*

A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib

Trial Protocol ID
USOR 22244_IM048022

Investigator
Jose Méndoza, M.D.

A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM)

Trial Protocol ID
USOR 20285_IST-337

Investigator
Mohit Narang, M.D.

A phase II trial of Daratumumab, Lenalidomide and Dexamethasone (DRd) in combination with Selinexor for patients with newly diagnosed multiple myeloma

Trial Protocol ID
USOR 21367_GRAIL-012

Investigator
Jason Taksey, M.D.

The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population

Trial Protocol ID
AZA-MDS-006

Investigator
Mohit Narang, M.D.

Connect® Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry